DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device
Recruiting
Observational Study
Intracranial Aneurysm
Flow Diverter
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 158 (estimated)
- Sponsor
- Acandis GmbH · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To analyse the clinical safety and efficacy of the DERIVO® 2heal® Embolisation Device in the standard clinical routine of flow diversion treatment with respect to the mid- and long-term clinical and angiographic outcomes.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient to be treated with DERIVO® 2heal® Embolisation Device due to intracranial aneurysm according to IFU
* Age \> 18 years
* Signed Informed Consent Form
* Patient scheduled to be treated for only one target aneurysm except multiple aneurysms located in the same target zone…
Contacts